Table 7.
Outcomes of IMRT for NPC in published series.
| Author (year) | Number of patients | Treatment period | Median follow-up (m) | Stage | Treatment arms | Time point (y) | LC (LRFS) | RC (NRFS) | DMFS | OS |
|---|---|---|---|---|---|---|---|---|---|---|
| Tham et al. (2009) [6] | 195 | 2002–2005 | 37 | I–IVB | RT or CRT | 3 | 93% | NR | 89% | 94% |
| Lee et al. (2009) [5] | 68 | 2003–2005 | 30 | I–IVB | RT or CRT | 2 | 93% | 91% | 85% | 80% |
| Su et al. (2012) [9] | 198 | 2001–2008 | 51 | I–IIB | RT | 5 | 98% | NR | 98% | 97%∗ |
| Lai et al. (2011) [10] | 512 | 2003–2006 | 53 | I–IVB | RT or CRT | 5 | 93% | 97% | 84% | NR |
| Lin et al. (2010) [7] | 370 | 2003–2007 | 31 | IIB–IVB | RT or CRT | 3 | 95% | 97% | 81% | 89% |
| Ng et al. (2011) [8] | 193 | 2005–2007 | 30 | I–IVB | RT or CRT | 2 | 95% | 96% | 90% | 92% |
| Peng et al. (2012) [11] | 306 | 2003–2008 | 42 | I–IVB | RT or CRT | 5 | 90.5% | 91.7% | NR | 79.6% |
| Wang et al. (2012) [29] | 138 | 2006–2009 | 23 | I–IVB | RT or CRT | 3 | 94% | 96% | 80% | 83% |
| This study | 190 | 2007–2012 | 32 | I–IVB | RT or CRT or ART | 3 | 96% | 98% | 92% | 86% |
RT: radiation therapy alone; CRT: chemoradiotherapy; ART: radiation therapy concurrent with anti-EGFR Mab therapy; LC: local control; LRFS: local relapse-free survival; RC: regional control; NRFS: nodal relapse-free survival; DMFS: distant metastases-free survival; OS: overall survival; NR: not reported; ∗disease-specific survival.